Bellemin Jean-Marc 4
4 · IOVANCE BIOTHERAPEUTICS, INC. · Filed Mar 5, 2025
Insider Transaction Report
Form 4
Bellemin Jean-Marc
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-03-03+58,590→ 87,938 total - Exercise/Conversion
Restricted Stock Units
2025-03-03−58,590→ 70,317 total→ Common Stock (58,590 underlying) - Tax Payment
Common Stock
2025-03-03$4.04/sh−31,734$128,205→ 56,204 total
Footnotes (7)
- [F1]Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
- [F2]Represents common stock owned by the Reporting Person, excluding common stock purchased pursuant to the Issuer's 2020 Employee Stock Purchase Plan.
- [F3]Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
- [F4]Represents common stock remaining after deducting the common stock withheld for taxes.
- [F5]Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- [F6]The remaining RSUs will vest in equal quarterly installments.
- [F7]Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person.